-
Affiliation
-
Faculty of Pharmacy, Department of Pharmacy 病態生理学講座 (Shiba-Kyoritsu)
-
Position
-
Professor
![]() KEIO RESEARCHERS INFORMATION SYSTEM |
Details of a Researcher
このページはJavascriptを使用しています。すべての機能を使用するためにはJavascript を有効にする必要があります。
Hattori, Yutaka
|
慶應義塾大学病院, 内科, 研修医
川崎市立川崎病院, 内科, 医員
国立がんセンター研究所, 分子腫瘍学部, 研究員
Memorial Sloan-Kettering Cancer Center, Hematologic Oncology
慶應義塾大学医学部内科学教室, 血液・感染・リウマチ内科, 助手
Keio University, School of Medicine
University, Graduated
医学博士, Keio University, 1991.02
K-sam, an amplified gene in stomach cancer, is a member of the heparin-binding growth factor receptor genes.
医師免許, 1984.06
日本内科学会認定内科医, 1987.12
日本内科学会指導医, 2000.05
日本血液学会認定血液専門医, 2004.10
日本臨床腫瘍学会暫定指導医, 2005.09
フィジカルアセスメントに基づく症例解析と薬物治療
青森達、大林恭子、齋藤義正、里美貴、須賀達夫、中村智徳、服部 豊、松下麻衣子, 京都廣川書店, 2021.08, Page: 134
Scope: 心不全の病態、慢性心不全の薬物治療, Contact page: 10-14
臨床薬学テキストシリーズ 血液・造血器/感染症/悪性腫瘍
望月眞弓・加藤裕久・服部 豊, 中山書店, 2021.05, Page: 395
Scope: 修得すべき知識の概要、血液疾患の検査, Contact page: 2,3,15-25
多発性骨髄腫 新規治療薬の使い方・考え方
HATTORI YUTAKA, 先端医学社(東京), 2017.06
Scope: 開発中の薬剤 pp174-179
骨髄腫治療を理解するためのMyeloma Biology
HATTORI YUTAKA, 医薬ジャーナル社(大阪), 2017.05
Scope: 肝細胞増殖因子(HGF)およびその受容体(c-MET) pp137-144
悪性腫瘍の薬、病態、治療 スタンダード薬学シリーズ 医療薬学 IV.薬理、病態・薬物治療(4) 日本薬学会編
服部 豊, 東京化学同人, 2017.04
Scope: pp207-218
SORT1/LAMP2-mediated Extracellular Vesicle Secretion and Cell Adhesion Are Linked to Lenalidomide Resistance in Multiple Myeloma
Tomofumi Yamamoto, Jun Nakayama, Yusuke Yamamoto, Masahiko Kuroda, Yutaka Hattori, Takahiro Ochiya
Blood Advance (American Society of Hematology) 2022.01
Research paper (scientific journal), Accepted
Integrin β5 and β7 expression in lenalidomide-resistant multiple myeloma cells
Yutaka Hattori · Takumi Futo · Ryo Uozaki · Daiju Ichikawa · Takashi Yamaguchi · Tomofumi Yamamoto · Maiko Matsushita · Maki Hirao
International Journal of Hematology (Springer Nature) 2022
Research paper (scientific journal), Joint Work, Accepted
Nagase K., Edatsune G., Nagata Y., Matsuda J., Ichikawa D., Yamada S., Hattori Y., Kanazawa H.
Biomaterials Science (Biomaterials Science) 9 ( 21 ) 7054 - 7064 2021.11
Research paper (scientific journal), Joint Work, Accepted, ISSN 20474830
Nagase K., Ishii S., Ikeda K., Yamada S., Ichikawa D., Akimoto A.M., Hattori Y., Kanazawa H.
Scientific Reports (Nature Research) 10 ( 1 ) 2020.12
Research paper (scientific journal), Joint Work, Accepted
Characteristics of a novel target antigen against myeloma cells for immunotherapy
Matsushita M., Saito S., Yokoe S., Ichikawa D., Hattori Y.
Vaccines (MDPI) 8 ( 4 ) 1 - 13 2020.12
Research paper (scientific journal), Joint Work, Accepted
Molecular analysis and drug discovery targeting extramedullary disease in high-risk multiple myeloma
Hattori, Yutaka
科学研究費補助金研究成果報告書 2019
Development of novel immunotherapy targeting leukemic stem cells.
Hattori, Yutaka
科学研究費補助金研究成果報告書 2016
Hattori, Yutaka
科学研究費補助金研究成果報告書 2016
Hattori, Yutaka
科学研究費補助金研究成果報告書 2011
Integrin β5 and β7 expression in lenalidomide-resistant multiple myeloma cells
Hattori Y., Futo T., Uozaki R., Ichikawa D., Yamaguchi T., Yamamoto T., Matsushita M., Hirao M.
International Journal of Hematology (International Journal of Hematology) 115 ( 4 ) 605 - 608 2022.04
ISSN 09255710
Treatment of relapsed and refractory multiple myeloma
Hisako Kunieda, Maki Hirao, Yutaka Hattori
Hematological Malignancies (ver. 2) (Nihon Rinsho Co. Ltd) 78 ( 増刊号3 ) 638 - 644 2020.08
Article, review, commentary, editorial, etc. (other), Joint Work
A Challenge to Aging Society by microRNA in Extracellular Vesicles: microRNA in Extracellular Vesicles as Promising Biomarkers and Novel Therapeutic Targets in Multiple Myeloma.
Yamamoto T, Kosaka N, Hattori Y, Ochiya T.
J Clin Med. 7 ( 3 ) E55 2018.03
Article, review, commentary, editorial, etc. (scientific journal), Joint Work
下痢の受診勧奨のポイント
HATTORI YUTAKA
日本薬剤師会雑誌 (日本薬剤師会) 67 ( 10 ) 1439 - 1441 2015
Article, review, commentary, editorial, etc. (scientific journal), Single Work
便秘の受診勧奨のポイント
HATTORI YUTAKA
日本薬剤師会雑誌 (日本薬剤師会) 67 ( 7 ) 957 - 961 2015
Article, review, commentary, editorial, etc. (scientific journal), Single Work
A novel candidate for immunological target in treatment of multiple myeloma.
Matsushita M, Saito S, Mori K, Yokoe S, Ichikawa D, Hattori Y
An AACR Special Conference on Tumor Immunology and Immunotherapy (Boston, U.S.A.) ,
Poster presentation, American Association of Cancer Research
Dedifferentiation by reprogramming genes augmented drug resistance and clonal growth in myeloma cells
Tsuji H, Futo T, Samata K, Yamamoto T, Ichikawa D, Matsushita M, Hattori Y
81th annual meeting of the Japanese Society of Hematology (Tokyo) ,
Poster presentation, Japanese Society of Hematology
Diverse molecular mechanisms of lenalidomide resistance in multiple myeloma cells
Futo T, Uozaki R, Yamaguchi T, Yamamoto T, Tsuji H, Samata K, Ichikawa D, Matsushita M, Hattori Y
81th Annual meeting of the Japanese Society of Hematology (Tokyo) ,
Oral presentation (general), Japanese Society of Hematology
Novel compound derived from natural products, komaroviquinone, showed anti-myeloma activity in vivo
Samata K, Okayama M, Fujimori K, Yamamoto T, Ichikawa D, Matsushita M, Suto Y, Iwasaki G, Yamada T, Hattori Y
78th annual meeting of the Japanese cancer association,
Oral presentation (general)
天然物由来成分komaroviquinone及びその誘導体群はin vivoにおいて抗骨髄腫活性を示す
佐俣光一、岡山幹夫、藤森宏太、西山沙織、辻宏樹、不藤拓海、市川大樹、松下麻衣子、岩崎源司、須藤豊、山田健人、平尾磨樹、国枝尚子、長田眞、服部豊
日本薬学会生物系薬学部会第20回Pharmaco-Hematologyシンポジウム (東京) ,
Oral presentation (general), 日本薬学会生物系薬学部会
新たな概念によるハイリスク骨髄腫の予後不良に関わる分子機構の探索と克服薬の開発
MEXT,JSPS, Grant-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (C), Principal investigator
ハイリスク造血器腫瘍の髄外病変に着目した新規ターゲットの探索と創薬研究
MEXT,JSPS, Grant-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (C), Principal investigator
Drug discovery based on novel concept for overcoming high-risk myeloma which is still intractable despite of recent progress in the treatment
MEXT,JSPS, Grant-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (C), Principal investigator
難治性多発性骨髄腫に対する骨髄腫瘍血管新生を標的とした遺伝子治療法の開発と実践.
慶應義塾大学, Keio Gijuku Academic Development Funds, Research grant, No Setting
腫瘍血管新生を標的とした難治性多発性骨髄腫の新規治療法の開発と実践.
財団法人 がん研究振興財団, 第35回がん研究助成金, Research grant, No Setting
フェニルフタルイミド修飾体及びそれを有効成分とする抗癌剤
Date applied: 2016-207402 2016.10
Patent, Joint
化合物もしくはその薬理学的に許容される塩、抗腫瘍剤、又は活性酸素産生剤
Date applied: 特願2016-031897 2016.02
Date published: 特開2017-149658 2017.08
Patent, Joint
ペプチド、樹状細胞、細胞傷害性T細胞、白血病ワクチン、及び白血病受動免疫療法剤
Date applied: 特願2013-194119 2013.09
Date published: 特開2015-71543 2015.04
Date issued: 特許第6204130号 2017.09
Patent, Joint
がん免疫療法
Date applied: 特願2012-132288 2012.06
Date published: 特開2013-256454 2013.12
Date issued: 特許第5984113号 2016.08
Patent, Joint
多発性骨髄腫に伴う骨融解症状を診断するための診断剤及びその使用法.
Date applied: P2011-17058 2011.01
Date published: 特開2012-159297 2012.08
Patent, Joint
がん集学的治療研究財団第29回一般研究助成
服部豊., 2008.12, がん集学的治療研究財団, サリドマイドを用いた多発性骨髄腫に対する自家造血幹細胞移植後の維持・強化療法.
日本白血病研究基金平成20年度一般研究賞
服部豊., 2008.10, 日本白血病研究基金, 多発性骨髄腫の再発の分子機構とその克服.
高松宮妃癌研究癌研究基金研究助成受賞
服部豊., 2008.01, 高松宮妃癌研究癌研究基金, 難治性造血器腫瘍に対するポストサリドマイド世代の画期的治療法の開発.
がん集学的治療研究財団 第29回一般研究助成受賞
2008
日本白血病研究基金一般研究賞受賞
2008
STUDY OF MAJOR FIELD: (CLINICAL PHYSIOLOGY AND THERAPEUTICS)
2022
SPECIALIZED CANCER CLINICAL TRAINING
2022
SEMINAR: (CLINICAL PHYSIOLOGY AND THERAPEUTICS)
2022
RESEARCH FOR BACHELOR'S THESIS 1
2022
PRIOR LEARNING FOR CLINICAL PRACTICE 5
2022
The Pharmaceutical Society of Japan,
The Japanese Society of Myeloma,
American Society of Hematology,
The Japanese Cancer Association,
The Japanese Society of Hematology,
president, The 48th Annual Meeting of the Japanese Society of Hematology
Chairman, The pharmaceutical Society of Japan, the 22th Pharmaco-Hematology Symposium
director, Japanese Society of Myeloma
Editorial Board, Japanese Journal of Clinical Oncology
Board of Councillors、Editorial provision committee , Japanese Society of Hematology